Close Menu

So Much for New Ideas

The Wall Street Journal's Health Blog reports that Pfizer named Martin Mackay as the new chief of their struggling R&D program. Jacob Goldstein adds that Mackay, who has been at Pfizer for over ten years, is an odd choice since Pfizer had been looking to bring in fresh blood. Pfizer also announced the launch of a dedicated biotech unit in San Franciso that will be run by Corey Goodman.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.